The Index can be summarised by the question: if you gave the same molecule to two different companies in early phase, which would make the best of it?

Based on systematic, objective analysis of each company’s performance between 2011 and 2016, the 2017 ranking sees the return of some major pharma companies to the Top 10, with Bristol-Myers Squibb and Merck rising sharply, and continued strong performance from the mid-size, specialist players – Biogen tops the Index for the first time in its history. Johnson & Johnson, who had led the Index for 5 of the previous 6 years, continue to perform strongly, but were leapfrogged by outstanding performance from Biogen, AbbVie and Gilead.

Seven of the 13 historic big pharma companies, which received 14 approvals in 2015, came up empty-handed in 2016

Mike Rea

Based on systematic, objective analysis of each company’s performance between 2011 and 2016, the 2017 ranking sees the return of some major pharma companies to the Top 10, with Bristol-Myers Squibb and Merck rising sharply, and continued strong performance from the mid-size, specialist players – Biogen tops the Index for the first time in its history. Johnson & Johnson, who had led the Index for 5 of the previous 6 years, continue to perform strongly, but were leapfrogged by outstanding performance from Biogen, AbbVie and Gilead.

For a more in-depth look at this year’s Pharmaceutical Innovation Index, details of the methodology and the top 30 companies, and to download the White Paper, please visit PII live on our website. For questions and comments please contact pii@ideapharma.com.